Selective serotonin reuptake inhibitors are clinically prescribed antidepressants that act by increasing the local concentration of neurotransmitter at synapses and in extracellular spaces via blockade of the serotonin transporter. Here we report x-ray structures of engineered thermostable variants of the human serotonin transporter bound to the antidepressants sertraline, fluvoxamine, and paroxetine. The drugs prevent serotonin binding by occupying the central substrate binding site and stabilizing the transporter in an outward-open conformation.
in modulation of transporter activity by altering the kinetics of ligand dissociation from the central site [11] [12] [13] . Addictive substances such as cocaine and amphetamine bind to monoamine transporters and can either inhibit NT transport or promote NT efflux, respectively 14, 15 . Selective serotonin reuptake inhibitors (SSRIs) are a class of small molecules that are highly selective for SERT over DAT and NET and that inhibit 5-HT reuptake with nanomolar potency 16 . SSRIs are typically used as antidepressants in the treatment of major depressive disorder and anxiety disorder 1 and are the most widely prescribed antidepressants 17 .
SSRIs have a diverse chemical structure and, in many instances, they do not share common structural motifs. The diversity of SSRI chemical structures, in turn, results in compounds with substantial pharmacological differences 18 . Sertraline and fluvoxamine, as examples, differ in chemical structure from other SSRIs such as paroxetine, citalopram, and fluoxetine ( Fig. 1) , and as a consequence these compounds bind with a range of affinities to SERT. Sertraline contains a tetrahydronaphthalene ring system linked to a secondary amine together with a meta and para substituted dichlorophenyl group. Fluvoxamine, by contrast, consists of a 2-aminoethyloxime moiety attached to a methyoxybutyl group, and a phenyl group containing a trifluoronated methyl at the para positon. Fluoxetine also contains a trifluoronated aromatic group but is instead coupled to a phenylpropylamine moiety. Paroxetine and citalopram also differ substantially in the structures of their aromatic, amine, and halogenated substitutents.
Recently, we solved x-ray structures of a thermostabilized, transport-inactive construct of human SERT, deemed the ts3 construct, in complex with the SSRIs paroxetine and citalopram 8 .
We employed the thermostabilized variant of SERT in order to facilitate purification and crystallization 19, 20 . One of the thermostabilizing mutations, however, involves a residue (Thr439Ser) that is directly positioned within the central binding site, in close proximity to the bound SSRIs. Moreover, recent computational modeling of a wild-type SERT-paroxetine complex, in which the structure of the Drosophila DAT was used as a template for the SERT structure, yielded a pose for paroxetine in the SERT binding site that is different from that found in the SERT ts3 crystal structure 21 . In light of the computational study and because residue 439 is near the central binding site, we were motivated to determine crystal structures of SERT bound with SSRIs where residue 439 is the wild-type threonine amino acid.
Despite the importance of SSRIs in medicine and in the biophysical study of SERT, there is little structural explanation for how these diverse ligands bind to SERT 22 . Until recently, the structural understanding of how SSRIs bind to SERT has been largely guided by studies of the bacterial homolog LeuT 23, 24 , computational modeling [25] [26] [27] [28] [29] , and more recently, the structures of SERT in complex with paroxetine and citalopram 8 . In order to accommodate various SSRIs within the central binding site, we reasoned that residues lining the central binding site might adopt different conformations. Thus we determined x-ray structures of Thr439 ts2 SERT in complex with paroxetine and the structure of the ts3 transporter bound to sertraline and fluvoxamine. These structures provide insight into how different SSRIs are bound within the central binding site of SERT.
To probe the capacity of the ts3 and ts2 transporters to bind antidepressants we first carried out binding studies using 3 H-paroxetine ( Fig. 2a ). Paroxetine binds with a dissociation constant (K d ) value of 1.09 ± 0.08 and 0.63 ± 0.07 nM to the ts3 and ts2 variants (student's ttest, p-value less than 0.05). Next, we measured the K i values for various SSRIs by competition with 3 H-paroxetine. With the exception of sertraline, SSRIs bind with slightly lower affinity to ts3 vs. ts2 (Fig. 2b ). S-citalopram exhibited a K i of 10 ± 1 and 7 ± 1 nM (p-value greater than 0.05); sertraline, 2.0 ± 0.2 and 7 ± 1 nM (p-value greater than 0.05); S-fluoxetine, 35 ± 3 and 10 ± 1 nM (p-value less than 0.05); R-fluoxetine, 41 ± 4 and 9 ± 1 nM (p-value less than 0.05); and fluvoxamine, 69 ± 9 and 10 ± 2 nM (p-value less than 0.05). These dissociation constants and the relative differences of the dissociation constants between the SSRIs agree well with previous reports 30 . The presence of the Y110A mutant in both the ts3 and the ts2 variants renders them inactive in 5-HT transport 19 .
The structure of paroxetine bound to ts2 was determined using diffraction data that extend to Bragg spacing of 3.6 Å. Electron density for several of the side chains for residues in the intracellular gate and within the C-terminal hinge and helix were also better resolved in the ts2 structure reported here in comparison to the previously reported ts3 structure, thus allowing for more complete modeling of these regions (Extended Data Fig. 1 ), including part of the recognition sequence for SEC24C 31, 32 . Despite the medium resolution of the diffraction data, the electron density features in the central site are of sufficient quality to allow us to position paroxetine. We find that the piperidine ring is best accommodated in subsite A, the benzodioxol in subsite B, and the fluorophenyl group in subsite C ( Fig. 3a , Table 1 ). Fitting of paroxetine in the opposite orientation with the benzodioxol in subsite C, and the fluorophenyl in subsite B yields a poor fit to the electron density and produces clashes in subsite A and C (Extended Data The structure of the ts2 SERT variant in complex with paroxetine revealed only minor perturbations in the pose of the inhibitor and the conformations of residues involved in ligand binding in comparison to the ts3 -paroxetine structure ( Fig. 4a,b ). We believe this is because the hydroxyl group of threonine 439 faces subsite B, as does the serine at this position, and thus both are in a position to participate in interactions with ligands in the central site. We speculate that the ts2 variant has a higher affinity for paroxetine because, at least in part, the hydroxyl of Ser439 is closer to a ligand benzodioxol oxygen (3.9 Å) in comparison to the hydroxyl of Thr439 (5.2 Å). Further studies, at higher resolution, will be required to more definitively define transporter-ligand interactions.
The amine groups of sertraline and fluvoxamine also occupy subsite A, interacting with
Asp98 and Try95 ( Fig. 4c,d ) residues crucial for drug binding [34] [35] [36] . In subsite B, Ser439 is within 4.5 and 3.9 Å of the halide atoms of sertraline and fluvoxamine while aromatic interactions are formed between Tyr176 and the drugs. The side chain of Ile172 adopts a similar conformation as it does in the paroxetine state, fitting snuggly between substituents in subsites B and C. In subsite C, Phe341 forms a face-to-face interaction with the naphthalene ring of sertraline while Phe335 forms a face-to-edge interaction with the naphthalene moiety. In the fluvoxamine complex, Phe341 25 assumes a similar rotameric conformation as in the sertraline complex while the conformation of Phe335 is closer to that observed in the paroxetine structures.
Comparisons of the structures of the sertraline and fluvoxamine complexes to the previously determined structures of SERT with paroxetine and S-citalopram reveal important differences in the position of residues in subsite C. In the sertraline complex, relative to the paroxetine and S-citalopram complexes, Phe341 has flipped 'upward' to fill a space that is unoccupied by ligand and to interact with the naphthalene ring of sertraline; Phe335 undergoes a rotation of ~90° about its C-C bond (chi2) in order to accommodate the conformational change of Phe341 (Fig. 5a ). In the fluvoxamine complex, Phe341 is in a similar position as the sertraline complex, but Phe335 adopts a conformation more similar to that observed in the paroxetine and S-citalopram complexes (Fig. 5b,c) . We also note that Thr497 is also shifted by ~1 Å (Cα-Cα distance) in the sertraline and fluvoxamine complexes in comparison to the paroxetine complexes, likely because paroxetine is the only drug with a fluorinated substituent in subsite C, a substituent which interacts with Thr497.
Superposition of all four SSRI complexes revealed different placement of the various drug substituents within the central binding site ( Fig. 5d -f, Fig. 6 ) resulting in differences in van der Waals (>4 Å), aromatic (4.5-7 Å) 37 , and ionic (~4 Å) 38 
STRUCTURE DEPOSITION
The coordinates for the structure have been deposited in the Protein Data Bank under the accession codes 6AWN (ts2-paroxetine), 6AWP (ts3-fluvoxamine), 6AWO (ts3-sertraline), 6AWQ (ts3-sertraline-anomalous) (see Table 1 for details).
METHODS

SERT constructs
The ts3 variant 19, 20 contains the thermostabilizing mutations Tyr110Ala, Ile291Ala, Thr439Ser, as well as mutation of surface-exposed cysteines Cys554, Cys580, and Cys622 to alanine. The ts3 SERT gene is then fused to sequences to express a C-terminal GFP fluorophore followed by a twin Strep and, lastly, a His 10 purification tag. The mutation of Ser439 to threonine reverts the thermostabilizing mutation at position 439 of the ts3 construct to a threonine to then yield the ts2 construct. glycerol and 25 μM of the lipid mixture described above. Prior to crystallization, the purified SERT-8B6 complex was concentrated to 2 mg/ml; inhibitors were added to the protein solution to reach a final concentration of 50 µM and an additional amount of 8B6 Fab was added so that the final concentration of the added Fab was 1 µM.
Expression and purification
Crystallization
The SERT-Fab complex crystals were grown by hanging drop vapor diffusion at 4 °C using a ratio of 2 µl protein to 1 µl reservoir solution, the latter of which contained 50-100 mM Tris pH 8.5, 25-75 mM Li 2 SO 4 , 25-75 mM Na 2 SO 4 , 33.5 -36 % PEG 400 and 0.5% 6-aminohexanoic acid.
Data collection and structure refinement
Crystals were directly flash cooled in liquid nitrogen. Data was collected at the Advanced Photon Source (Argonne National Laboratory, beamline 24-ID-E) and at the Advanced Light Source (Lawrence Berkeley National Laboratory, beamline 5.0.2). X-ray data sets were processed using XDS 41 . Molecular replacement was performed using coordinates (PDB 5I6X code) from the prior structure determination of SERT 8 using the computer program PHASER 42 .
Several iterations of refinement and manual model building were carried out using PHENIX 43 and Coot 44 until the models converged to acceptable R-factors and stereochemistry. Polder 'omit' maps were calculated by excluding bulk solvent as previously described 33 .
Radioligand binding assays
Saturation binding experiments employed the scintillation proximity assay (SPA) 45 
Panels b-f show competition experiments between the binding of 3 H-paroxetine and cold
SSRIs, also on the ts3 and ts2 SERT variants, as described in panel a. Graphs depict the average of triplicate measurements from a representative experiment (error bars represent s.e.m.). 
